Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.

Mehdi A, Riazalhosseini Y.

Int J Mol Sci. 2017 Aug 16;18(8). pii: E1774. doi: 10.3390/ijms18081774. Review.

2.

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma.

Bendtsen MAF, Grimm D, Bauer J, Wehland M, Wise P, Magnusson NE, Infanger M, Krüger M.

Int J Mol Sci. 2017 Aug 10;18(8). pii: E1736. doi: 10.3390/ijms18081736. Review.

3.

Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression.

Sun W, Kato H, Kitajima S, Lee KL, Gradin K, Okamoto T, Poelllinger L.

Sci Rep. 2017 Aug 3;7(1):7190. doi: 10.1038/s41598-017-05685-3.

4.

HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.

Haase VH.

Hemodial Int. 2017 Jun;21 Suppl 1:S110-S124. doi: 10.1111/hdi.12567. Review.

5.

Hypoxia-inducible factor-2α stabilizes the von Hippel-Lindau (VHL) disease suppressor, Myb-related protein 2.

Okumura F, Joo-Okumura A, Nakatsukasa K, Kamura T.

PLoS One. 2017 Apr 10;12(4):e0175593. doi: 10.1371/journal.pone.0175593. eCollection 2017.

6.

The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.

Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S, Oyama T, Takeda S, Ray CE, Dong Z, Berge M, Hakimi AA, Monette S, Lekaye CL, Koutcher JA, Leslie CS, Creighton CJ, Weinhold N, Lee W, Tickoo SK, Wang Z, Cheng EH, Hsieh JJ.

Cell Rep. 2017 Mar 21;18(12):2893-2906. doi: 10.1016/j.celrep.2017.02.074.

7.

Forkhead Transcription Factor 3a (FOXO3a) Modulates Hypoxia Signaling via Up-regulation of the von Hippel-Lindau Gene (VHL).

Liu X, Cai X, Hu B, Mei Z, Zhang D, Ouyang G, Wang J, Zhang W, Xiao W.

J Biol Chem. 2016 Dec 2;291(49):25692-25705. Epub 2016 Oct 24.

8.

Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.

Hsieh JJ, Manley BJ, Khan N, Gao J, Carlo MI, Cheng EH.

Semin Cell Dev Biol. 2017 Apr;64:98-106. doi: 10.1016/j.semcdb.2016.09.002. Epub 2016 Sep 8. Review.

PMID:
27615548
9.

Capture-C reveals preformed chromatin interactions between HIF-binding sites and distant promoters.

Platt JL, Salama R, Smythies J, Choudhry H, Davies JO, Hughes JR, Ratcliffe PJ, Mole DR.

EMBO Rep. 2016 Oct;17(10):1410-1421. Epub 2016 Aug 8.

10.

Trial Watch: Proteasomal inhibitors for anticancer therapy.

Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L.

Mol Cell Oncol. 2014 Dec 1;2(2):e974463. doi: 10.4161/23723556.2014.974463. eCollection 2015 Apr-Jun. Review.

11.
12.

Parallel Regulation of von Hippel-Lindau Disease by pVHL-Mediated Degradation of B-Myb and Hypoxia-Inducible Factor α.

Okumura F, Uematsu K, Byrne SD, Hirano M, Joo-Okumura A, Nishikimi A, Shuin T, Fukui Y, Nakatsukasa K, Kamura T.

Mol Cell Biol. 2016 May 31;36(12):1803-17. doi: 10.1128/MCB.00067-16. Print 2016 Jun 15.

13.

Germline mutations in the VHL gene associated with 3 different renal lesions in a Chinese von Hippel-Lindau disease family.

Yuan P, Sun Q, Liang H, Wang W, Li L, Wang Y, Deng H, Lai L, Chen X, Zhou X.

Cancer Biol Ther. 2016 Jun 2;17(6):599-603. doi: 10.1080/15384047.2016.1167293. Epub 2016 Apr 8.

14.

The role of cullin 5-containing ubiquitin ligases.

Okumura F, Joo-Okumura A, Nakatsukasa K, Kamura T.

Cell Div. 2016 Mar 9;11:1. doi: 10.1186/s13008-016-0016-3. eCollection 2016. Review.

15.

Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2α expression and activity in cancer.

Bouquerel P, Gstalder C, Müller D, Laurent J, Brizuela L, Sabbadini RA, Malavaud B, Pyronnet S, Martineau Y, Ader I, Cuvillier O.

Oncogenesis. 2016 Mar 14;5:e209. doi: 10.1038/oncsis.2016.13.

16.

Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.

Fan Y, Li H, Ma X, Gao Y, Bao X, Du Q, Ma M, Liu K, Yao Y, Huang Q, Zhang Y, Zhang X.

Oncotarget. 2016 Apr 5;7(14):18280-94. doi: 10.18632/oncotarget.7807.

17.

WSB1 promotes tumor metastasis by inducing pVHL degradation.

Kim JJ, Lee SB, Jang J, Yi SY, Kim SH, Han SA, Lee JM, Tong SY, Vincelette ND, Gao B, Yin P, Evans D, Choi DW, Qin B, Liu T, Zhang H, Deng M, Jen J, Zhang J, Wang L, Lou Z.

Genes Dev. 2015 Nov 1;29(21):2244-57. doi: 10.1101/gad.268128.115.

18.

The Dawning of a New Day in CKD Anemia Care?

Lenihan CR, Winkelmayer WC.

J Am Soc Nephrol. 2016 Apr;27(4):968-70. doi: 10.1681/ASN.2015091009. Epub 2015 Oct 22. No abstract available.

19.

Prognostic Significance of Hypoxia-Inducible Factor Expression in Renal Cell Carcinoma: A PRISMA-compliant Systematic Review and Meta-Analysis.

Fan Y, Li H, Ma X, Gao Y, Chen L, Li X, Bao X, Du Q, Zhang Y, Zhang X.

Medicine (Baltimore). 2015 Sep;94(38):e1646. doi: 10.1097/MD.0000000000001646. Review.

20.

Repression of hypoxia-inducible factor α signaling by Set7-mediated methylation.

Liu X, Chen Z, Xu C, Leng X, Cao H, Ouyang G, Xiao W.

Nucleic Acids Res. 2015 May 26;43(10):5081-98. doi: 10.1093/nar/gkv379. Epub 2015 Apr 20.

Supplemental Content

Support Center